Literature DB >> 12191514

Cytokine profiles using whole-blood assays can discriminate between tuberculosis patients and healthy endemic controls in a BCG-vaccinated population.

Rabia Hussain1, Arnawaz Kaleem, Firdaus Shahid, Maqboola Dojki, Bushra Jamil, Hammad Mehmood, Ghaffar Dawood, Hazel M Dockrell.   

Abstract

Whole-blood assays (WB) provide a simple tool for assessing immune cytokine profiles which may be useful laboratory predictors of early disease, aiding the evaluation of new tuberculosis (TB) vaccines and offering insights into disease pathogenesis. Although BCG does not provide protection against pulmonary disease in TB endemic areas, it does modulate immune responses to mycobacterial antigens. It is important, therefore, to evaluate any new tool in an endemic setting in both BCG vaccinees and patients with tuberculosis. We have assessed the optimal conditions in terms of dose and kinetics of those cytokines which are released early (TNF-alpha, IL6 and TGF-beta, IL10) or (interferon [IFN]-gamma and IL5) in WB cultures stimulated with mitogens and mycobacterial antigens. Responses were studied in parallel in untreated TB patients and endemic control groups. Optimal responses to LPS (predominantly monocyte-derived) occurred on days 1-2, whereas for PHA (predominantly T-cell-derived), they were on days 3-5. Secreted Mycobacterium tuberculosis culture filtrate proteins (CFP) provided a stronger stimulus for monocyte-derived cytokines compared to PPD, but both antigens were comparable for induction of T-cell cytokines. Using unpaired Student's t-tests, pulmonary tuberculosis patients (P.TB; n=11), in response to CFP, showed higher monocyte-derived IL6 (p=0.023) and IL10 (p=0.042) compared to endemic controls (EC; n=13), and significantly suppressed T-cell-derived IFN-gamma (p=0.028) and IL5 (p=0.012) secretion but increased IL10 (p=0.047) on day 5, indicating that CFP is a strong stimulus for IL10 secretion in pulmonary TB patients. Extrapulmonary TB patients (E.TB; n=6) showed no elevation of early monocyte-derived cytokines to either PPD or CFP, but showed a marked suppression of the T-cell-derived cytokines IFN-gamma (PPD, p=0.015; CFP, p=0.05) and IL5 (PPD, p=0.05; CFP, p=0.015). Cytokine analysis in WB cultures is, therefore, able to discriminate between active tuberculosis infection and nondiseased healthy controls.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12191514     DOI: 10.1016/s0022-1759(02)00092-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  37 in total

1.  Phosphorylation of glycogen synthase kinase-3β in metabolically abnormal obesity affects immune stimulation-induced cytokine production.

Authors:  C-L Yen; W-C Chao; C-H Wu; Y-F Huang; C-S Chang; Y-S Tsai; C-F Lin; C-C Shieh
Journal:  Int J Obes (Lond)       Date:  2014-05-23       Impact factor: 5.095

2.  Antigen discovery: a postgenomic approach to leprosy diagnosis.

Authors:  Romulo Aráoz; Nadine Honoré; Sungae Cho; Jong-Pill Kim; Sang-Nae Cho; Marc Monot; Caroline Demangel; Patrick J Brennan; Stewart T Cole
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Association of antigen-stimulated release of tumor necrosis factor-alpha in whole blood with response to chemotherapy in patients with pulmonary multidrug-resistant tuberculosis.

Authors:  Seok-Yong Eum; Ye-Jin Lee; Jin-Hong Min; Hyun-Kyung Kwak; Min-Sun Hong; Ji-Hye Kong; Soo-Hee Hwang; Seung-Kyu Park; Jason J Leblanc; Laura E Via; Clifton E Barry; Sang-Nae Cho
Journal:  Respiration       Date:  2010-02-10       Impact factor: 3.580

4.  Endogenously activated interleukin-4 differentiates disease progressors and non-progressors in tuberculosis susceptible families: a 2-year biomarkers follow-up study.

Authors:  Rabia Hussain; Najeeha Talat; Ambreen Ansari; Firdaus Shahid; Zahra Hasan; Ghaffar Dawood
Journal:  J Clin Immunol       Date:  2011-07-14       Impact factor: 8.317

5.  Molecular characterization of clinical isolates of Mycobacterium tuberculosis and their association with phenotypic virulence in human macrophages.

Authors:  K C Wong; W M Leong; H K W Law; K F Ip; J T H Lam; K Y Yuen; P L Ho; W S Tse; X H Weng; W H Zhang; S Chen; W C Yam
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

6.  IgG1 antimycobacterial antibodies can reverse the inhibitory effect of pentoxifylline on tumour necrosis factor alpha (TNF-alpha) secreted by mycobacterial antigen-stimulated adherent cells.

Authors:  S M Thakurdas; Z Hasan; R Hussain
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

7.  IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia.

Authors:  Helena del Corral; Sara C París; Nancy D Marín; Diana M Marín; Lucelly López; Hanna M Henao; Teresita Martínez; Liliana Villa; Luis F Barrera; Blanca L Ortiz; María E Ramírez; Carlos J Montes; María C Oquendo; Lisandra M Arango; Felipe Riaño; Carlos Aguirre; Alberto Bustamante; John T Belisle; Karen Dobos; Gloria I Mejía; Margarita R Giraldo; Patrick J Brennan; Jaime Robledo; María P Arbeláez; Carlos A Rojas; Luis F García
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

8.  In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response.

Authors:  Ilaria Sauzullo; Fabio Mengoni; Miriam Lichtner; Anna Paola Massetti; Raffaella Rossi; Marco Iannetta; Raffaella Marocco; Cosmo Del Borgo; Fabrizio Soscia; Vincenzo Vullo; Claudio Maria Mastroianni
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

9.  Biomarker changes associated with Tuberculin Skin Test (TST) conversion: a two-year longitudinal follow-up study in exposed household contacts.

Authors:  Rabia Hussain; Najeeha Talat; Firdaus Shahid; Ghaffar Dawood
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

10.  Complex cytokine profiles induced by BCG vaccination in UK infants.

Authors:  Maeve K Lalor; Steven G Smith; Sian Floyd; Patricia Gorak-Stolinska; Rosemary E Weir; Rose Blitz; Keith Branson; Paul E Fine; Hazel M Dockrell
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.